concept

MYELIN

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MYELIN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1148Connections

17Hypotheses

0Analyses

50Outgoing

50Incoming

7Experiments

0Debates

Summary

MYELIN is a concept in neurodegeneration research. Key relationships include: activates, associated with, inhibits. Associated with ALS, Aging, Als. Connected to 472 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	MYELIN
Key Genes/Proteins	ACAT1, ACETYL-COA, ACHE, ACTB, AGING, AKT
Related Diseases	aging, Aging, Als, ALS, Alzheimer
Related Pathways	Akt

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Myelin and White Matter Dysfunction in 4R-Tauopathies

mechanism · 2316 words

→

Pathway Diagram

graph TD
    MYELIN["MYELIN"]
    MYELIN -->|"regulates"| Aging["Aging"]
    MYELIN -->|"causes"| ALS["ALS"]
    MYELIN -->|"causes"| Neuropathy["Neuropathy"]
    MYELIN -->|"causes"| Autoimmune["Autoimmune"]
    MYELIN -->|"activates"| Parkinson["Parkinson"]
    MYELIN -->|"activates"| Dementia["Dementia"]
    MYELIN -->|"activates"| Alzheimer["Alzheimer"]
    MYELIN -->|"expressed in"| Tumor["Tumor"]
    oligodendrocytes["oligodendrocytes"] -->|"produces"| MYELIN
    WAM["WAM"] -->|"inhibits"| MYELIN
    Oligodendrocyte["Oligodendrocyte"] -->|"regulates"| MYELIN
    aging["aging"] -->|"causes"| MYELIN
    AQUAPORIN_4["AQUAPORIN-4"] -.biomarker for.-> MYELIN
    PMP22["PMP22"] -->|"causes"| MYELIN
    COMPLEMENT["COMPLEMENT"] -->|"activates"| MYELIN
    AQP4["AQP4"] -->|"causes"| MYELIN
    ASTROCYTES["ASTROCYTES"] -->|"causes"| MYELIN

Outgoing (708)

Target	Relation	Type	Str
Neurodegeneration	activates	disease	1.00
Als	activates	disease	1.00
MICROGLIA	activates	gene	1.00
Inflammation	activates	disease	1.00
INFLAMMATION	activates	gene	1.00
ASTROCYTE	activates	gene	1.00
Alzheimer	activates	disease	0.95
Als	associated_with	disease	0.95
Multiple Sclerosis	therapeutic_target	disease	0.95
OLIGODENDROCYTE	activates	gene	0.90
MICROGLIA	associated_with	gene	0.90
NEURODEGENERATIVE DISEASES	activates	gene	0.90
Tumor	activates	disease	0.85
Multiple Sclerosis	associated_with	disease	0.85
Inflammation	associated_with	disease	0.85
Neuroinflammation	activates	disease	0.85
Multiple Sclerosis	activates	disease	0.85
Alzheimer'S Disease	associated_with	disease	0.80
MSR1	upregulates	gene	0.80
ALZHEIMER	activates	gene	0.80
ALZHEIMER'S DISEASE	activates	gene	0.80
ASTROCYTES	activates	gene	0.80
MBP	activates	gene	0.80
MOG	activates	gene	0.80
Oxidative Stress	activates	pathway	0.80
Apoptosis	activates	pathway	0.80
CYTOKINES	activates	gene	0.80
Aging	causes	disease	0.75
Multiple Sclerosis	causes	disease	0.75
OLIGODENDROCYTE	associated_with	concept	0.75
Als	regulates	disease	0.75
NEUROINFLAMMATION	associated_with	concept	0.75
Neuroinflammation	inhibits	disease	0.75
Als	causes	disease	0.75
Autoimmune	causes	disease	0.75
Multiple Sclerosis	regulates	disease	0.75
Aging	associated_with	disease	0.75
Neuropathy	causes	disease	0.75
Inflammation	interacts_with	disease	0.75
Parkinson	activates	disease	0.75
Neurodegeneration	therapeutic_target	disease	0.75
Multiple Sclerosis	biomarker_for	disease	0.75
Autoimmune	activates	disease	0.75
Alzheimer	therapeutic_target	disease	0.75
Neurodegeneration	biomarker_for	disease	0.75
Phagocytosis	activates	pathway	0.70
ALZHEIMER	therapeutic_target	gene	0.70
NEUROTOXICITY	activates	gene	0.70
ALZHEIMER'S DISEASE	therapeutic_target	gene	0.70
OLIGODENDROCYTE	inhibits	gene	0.70

Incoming (440)

Source	Relation	Type	Str
NEURODEGENERATION	activates	gene	1.00
Oligodendrocytes	associated_with	cell_type	0.95
Oligodendrocyte	associated_with	cell_type	0.95
oligodendrocytes	produces	cell_type	0.90
Aging	causes	process	0.85
OLIGODENDROCYTE	associated_with	gene	0.80
TNF	activates	gene	0.80
OXIDATIVE STRESS	activates	gene	0.80
APOPTOSIS	activates	gene	0.80
TREM2	activates	gene	0.80
WAM	inhibits	cell_type	0.72
PARKINSON'S DISEASE	activates	gene	0.70
AGING	associated_with	gene	0.70
DISEASE-ASSOCIATED MICROGLIA	activates	gene	0.70
TAU	activates	gene	0.70
MICROGLIA	activates	gene	0.70
GENES	activates	gene	0.70
NEUROINFLAMMATION	activates	gene	0.70
STAT3	activates	gene	0.70
Oligodendrocyte	activates	entity	0.70
Oligodendrocyte	regulates	entity	0.70
COMPLEMENT	activates	gene	0.70
ROS	activates	gene	0.70
CX3CR1	co_discussed	gene	0.65
mitochondria	co_discussed	concept	0.65
ABCA1	co_discussed	gene	0.65
CLU	co_discussed	gene	0.65
MOG	associated_with	gene	0.65
AXON	associated_with	gene	0.65
CYP46A1	associated_with	gene	0.65
APP	associated_with	gene	0.65
BACE1	associated_with	gene	0.65
AMYLOID	associated_with	gene	0.65
OLIG2	co_discussed	gene	0.65
LRRK2	co_discussed	gene	0.65
NLRP3	co_discussed	gene	0.65
aging	causes	phenotype	0.64
AQUAPORIN-4	biomarker_for	gene	0.60
AQUAPORIN-4	associated_with	gene	0.60
AXON	activates	gene	0.60
RHOA	inhibits	gene	0.60
AMYLOID-BETA	inhibits	gene	0.60
ALS	regulates	gene	0.60
HMGCR	regulates	gene	0.60
DNA	causes	gene	0.60
TUBULIN	activates	gene	0.60
NEURON	activates	gene	0.60
ACHE	activates	gene	0.60
ELAVL3	activates	gene	0.60
CD8	activates	gene	0.60

Targeting Hypotheses (17)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Selective Acid Sphingomyelinase Modulation Therapy	0.920	neurodegeneration	Lipid raft composition changes in synapt
Neutral Sphingomyelinase-2 Inhibition for Synaptic Protectio	0.844	neurodegeneration	Lipid raft composition changes in synapt
SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysoso	0.734	neurodegeneration	What molecular mechanisms link elevated
SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduct	0.732	neurodegeneration	How do sphingomyelin/ceramide ratios spe
Senescence-Associated Myelin Lipid Remodeling	0.732	neurodegeneration	Senolytic therapy for age-related neurod

Selective Neutral Sphingomyelinase-2 Inhibition Therapy	0.731	neurodegeneration	Lipid raft composition changes in synapt
LXRβ-Selective Agonism as a Precision Therapeutic for APOE4-	0.721	neurodegeneration	What specific molecular mechanisms link
Sphingomyelin Synthase Activators for Raft Remodeling	0.692	neurodegeneration	Lipid raft composition changes in synapt
Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution	0.680	neurodegeneration	Neuroinflammation resolution mechanisms
ELF2-Mediated OPC Epigenetic Drift Drives Region-Dependent M	0.650	Alzheimer disease	Allen Mouse Brain Aging Atlas: cross-age
Oligodendrocyte Remyelination Enhancement	0.644	neurodegeneration	Gene expression changes in aging mouse b
Myelin Sulfatide Restoration	0.623	neurodegeneration	Gene expression changes in aging mouse b
BMP4 Pathway Inhibition for Oligodendrocyte Myelination Supp	0.620	neurodegeneration	Cell type vulnerability in Alzheimer's D
Myelin Breakdown-Amyloid Interaction Amplifies Cortical Agin	0.600	Alzheimer disease	Allen Mouse Brain Aging Atlas: cross-age
Oligodendrocyte-Targeted Myelin Sulfatide Restoration Therap	0.599	neurodegeneration	Which cell types show the most significa
MOG-IgG induces spinal cord demyelination through Fcγ recept	0.560	neuroinflammation	What are the specific pathophysiological
Oligodendrocyte Lineage Vulnerability: Early Myelination Dis	0.530	neurodegeneration	Cell type vulnerability debate in Alzhei

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (7)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Proposed experiment from debate on Senolytics targeting p16/p21+ senes	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$80,000
Proposed experiment from debate on Microglia activate astrocytes via I	falsification	Neuroinflammation	0.400	0.50	cell_line	proposed	$80,000
Iron Dyshomeostasis in MSA Pathogenesis Experiment	validation	Neurodegeneration	0.400	0.50	human	proposed	$2,280,000
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,100,000
Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
Validation: Membrane-Nucleation in iPSC Neurons	validation	Parkinson's Disease	0.400	0.50	human	proposed	$2,730,000
s:** - ALOX15 overexpression in healthy astrocytes should be protectiv	falsification	Neuroinflammation	0.400	0.50	mouse	proposed	$200,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Role and regulatory mechanism of GPR37 in neurological diseases. [PMID:40822851]	Liu S, Bai T, Liu X, Zhao W, Li X, Sui Y	Front Cell Neurosci	2025	1
Oligodendrocytes drive neuroinflammation and neurodegeneration in Parkinson's di [PMID:39913287]	Ma Q, Tian JL, Lou Y, Guo R, Ma XR, Wu J	Cell Rep	2025	1
Copy number deletion of PLA2G4A affects the susceptibility and clinical phenotyp [PMID:38816399]	Gao Z, Guo X, Sun Z, Wu S, Wang Q, Huang	Schizophrenia (Heidelb)	2024	1
Inflammation and Infection in Pain and the Role of GPR37. [PMID:36430912]	Zhang Q, Bang S, Chandra S, Ji RR	Int J Mol Sci	2022	1
Osteocalcin attenuates oligodendrocyte differentiation and myelination via GPR37 [PMID:34678058]	Qian Z, Li H, Yang H, Yang Q, Lu Z, Wang	Sci Adv	2021	1
GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain. [PMID:30010619]	Bang S, Xie YK, Zhang ZJ, Wang Z, Xu ZZ,	J Clin Invest	2018	1
Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: [PMID:21098459]	Mallat Z, Lambeau G, Tedgui A	Circulation	2010	1
Phospholipase A2 regulation of bovine endometrial (BEND) cell prostaglandin prod [PMID:18811942]	Godkin JD, Roberts MP, Elgayyar M, Guan	Reprod Biol Endocrinol	2008	1
Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomy [PMID:41692468]	["Hsu-Heng Lin", "Hui-An Chen", "Shyh-Je	Molecular genetics & genom	2026	0
Multi-omics analysis identifies SMPD1 as a key contributor in sphingolipid pathw [PMID:41428198]	["Aron Park", "Baeki E Kang", "Eun-Ju Ji	Genes & genomics	2026	0
Coenzyme Q10 Supplementation Modulates Hepatic Lipidomic Alterations and Attenua [PMID:41754105]	Go Y, Joung H, Han SY, Chung J	Nutrients	2026	0
SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immuno [PMID:41795144]	Xu Y, Liu X, Xu B, Li Q, Zhang L, Li C,	CNS neuroscience & therapeutic	2026	0
A multi-dimensional bioinformatic dissection of the molecular mechanisms in high [PMID:41191606]	Yu X MD, Lei J MSc, Du X MSc, He Y MSc,	Int J Surg	2026	0
Plasma metabolites may inhibit childhood obesity by regulating ferroptosis throu [PMID:41249848]	Wang JG, Pan XH, Li Y	Int J Obes (Lond)	2026	0
Multi-omics analysis identifies SMPD1 as a key contributor in sphingolipid pathw [PMID:41428198]	Park A, Kang BE, Jin EJ, Kim HJ, Lee CW	Genes Genomics	2026	0
AXL Promotes Ischemic Myelin Repair Through Alleviating Myelin Debris Deposition [PMID:41524160]	Jia J, Gan Y, Li J, Li L, Meng H et al.	Adv Sci (Weinh)	2026	0
Arachidonic acid analog AACOCF3 suppresses cPLA2-negative NSCLC cell proliferati [PMID:41544858]	Wang H, Wen Z, Jia Y, Tong X, Wang W et	Biochem Pharmacol	2026	0
Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomy [PMID:41692468]	Lin HH, Chen HA, Lin SJ, Hsu RH, Lee NC	Mol Genet Genomic Med	2026	0
Modification of the dermal matrix by senescence associated lipids and its functi [PMID:41690117]	["Jelleschitz S", "Kremslehner C", "Nage	Redox biology	2026	0
Endogenous Ceramide 24:1 Constrains Th17-Driven Neutrophilic Inflammation by Ant [PMID:41824764]	Liu H, Aili A, Kuang Z, Cao L, Li Z, Sha	Advanced science (Weinheim, Ba	2026	0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning MYELIN in their description or question text

MYELIN

Understanding Entity Pages

Summary

Wiki Pages (1)

Myelin and White Matter Dysfunction in 4R-Tauopathies

Pathway Diagram

Outgoing (708)

Incoming (440)

Targeting Hypotheses (17)

Mentioning Analyses (0)

Experiments (7)

Related Papers (20)

Debates (0)

Related Research

Selective Neutral Sphingomyelinase-2 Inhibition Therapy

LXRβ-Selective Agonism as a Precision Therapeutic for APOE4-Driven Myelin Defici

Sphingomyelin Synthase Activators for Raft Remodeling

Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution

ELF2-Mediated OPC Epigenetic Drift Drives Region-Dependent Myelin Dysfunction

Oligodendrocyte Remyelination Enhancement

Myelin Sulfatide Restoration

BMP4 Pathway Inhibition for Oligodendrocyte Myelination Support

Myelin Breakdown-Amyloid Interaction Amplifies Cortical Aging-Neurodegeneration

Oligodendrocyte-Targeted Myelin Sulfatide Restoration Therapy

MOG-IgG induces spinal cord demyelination through Fcγ receptor-dependent macroph

Oligodendrocyte Lineage Vulnerability: Early Myelination Disruption with Blocked